South Ko­re­an vac­cine mak­er pumps up its pro­duc­tion ca­pac­i­ty as Covid-19 de­mand holds steady

Af­ter re­ceiv­ing big in­vest­ments from the Bill and Melin­da Gates Foun­da­tion and the Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions, South Ko­re­an SK bio­science will ex­pand vac­cine pro­duc­tion with a $132 mil­lion in­vest­ment to add pro­duc­tion ca­pac­i­ty for both mR­NA and vi­ral-vec­tor vac­cines. The pro­duc­tion ca­pac­i­ty is ex­pect­ed to be op­er­a­tional by 2024.

The ex­pan­sion will add more than 1 mil­lion square feet of pro­duc­tion space in the city of An­dong, which is rough­ly 118 miles south­east of Seoul, Reuters re­port­ed. The fa­cil­i­ty gained GMP cer­ti­fi­ca­tion from the EU last week and makes vac­cines for the Eu­ro­pean mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER